Tirzepatide

Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. By engaging two incretin pathways at once, head-to-head trials suggest larger average…

Dual GIP and GLP-1 receptor agonist studied for metabolic and weight outcomes.

Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. By engaging two incretin pathways at once, head-to-head trials suggest larger average effects on weight and HbA1c than single-pathway GLP-1 agonists.

Overview

Tirzepatide is a synthetic peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-incretin profile has drawn significant clinical and research interest.

Mechanism of action

By engaging GIP and GLP-1 receptors simultaneously, tirzepatide influences insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.

Researched applications

• Metabolic and body-composition research
• Glycemic control studies
• Comparative incretin pharmacology

Quick facts

Property	Detail
Class	Dual GIP / GLP-1 receptor agonist
Half-life	~5 days
Dosing cadence	Once weekly (clinical)
Molecular weight	~4,814 Da
Storage	Lyophilized: freezer/refrigerator. Reconstituted: 2–8 °C, ≤28 days

Half-life

Reported half-life: Approximately 5 days.

Other metabolic & weight peptides

Tirzepatide sits in our metabolic & weight category. These are the other compounds in the same category, useful when you are deciding which reference page to read next.

• Semaglutide — A long-acting GLP-1 receptor agonist extensively studied for metabolic health.
• Retatrutide — Triple-receptor (GLP-1 / GIP / glucagon) agonist in late-stage clinical trials.

Tirzepatide head-to-head

• Semaglutide vs Tirzepatide: Side-by-side comparison of the two leading incretin peptides: mechanism, half-life, head-to-head trial data, and how to think about them.
• Tirzepatide vs Retatrutide: Dual-receptor vs triple-receptor: how the leading approved incretin compares to the most-watched next-generation molecule, side by side.
• Tirzepatide vs Mazdutide: The two leading dual-agonist incretins, one western (GIP+GLP-1), one Asia-first (GLP-1+glucagon). What their trials actually show.

Storage and shelf life

State	Conditions	Shelf life
Lyophilized (Powder)	Refrigerate 2–8°C (36–46°F) or freeze	12–24 months refrigerated; longer frozen
Reconstituted	Refrigerate 2–8°C only; no freezing	21–30 days typically
In Transit	Insulated packaging; ice packs	Minimize time; avoid heat exposure
MK-677 (Oral)	Room temp okay; cool/dry preferred	Per manufacturer; typically 12+ months

Sources

• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — NEJM / PubMed (accessed 2026-06-13): https://pubmed.ncbi.nlm.nih.gov/35658024/
• Tirzepatide vs Semaglutide (SURPASS-2) — NEJM / PubMed (accessed 2026-06-13): https://pubmed.ncbi.nlm.nih.gov/34170647/

Review status

This reference page was last reviewed on 2026-06-13 by the Clarity Wellness editorial team.

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

Head-to-head clinical trials (SURPASS-2) suggest greater average weight reduction with tirzepatide, but individual response varies and any clinical decision should be made with a licensed provider.

What does 'dual agonist' actually mean?

Tirzepatide activates two receptors (GIP and GLP-1) on the same molecule, in contrast to semaglutide which targets only GLP-1.